30 min
Reviewing ACTRIMS 2024 NeurologyLive® Mind Moments®
-
- Medicine
Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, Daniel Ontaneda, MD, an associate professor of neurology at the Cleveland Clinic Lerner College of Medicine, sat down to discuss the recently concluded Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum. Ontaneda, program committee vice-chair of the meeting, provided insight on a number of notable sessions and discussions that highlighted the recent advances in the MS field. In addition, he talked about the need to innovate clinical trials, ways to tackle progressive MS, and whether drug trials are truly assessing patients at the right time points. Furthermore, he discussed multi-stage trials, the potential role of Bruton tyrosine kinase (BTK) inhibitors, and how this year's meeting differs from previous ones.
Looking for more multiple sclerosis discussion? Check out the NeurologyLive® multiple sclerosis clinical focus page.
Episode Breakdown:
1:05 – Overviewing sessions from ACTRIMS Forum
13:10 – Innovating clinical trial design
16:15 – 2023 ACTRIMS vs 2024 ACTRIMS
20:20 – Neurology News Minute
23:30 – Testing combination approaches for progressive MS
26:45 – The impact of timing therapeutic interventions
This episode is brought to you by Medical World News, a streaming channel from MJH Life Sciences®. Check out new content and shows every day, only at medicalworldnews.com.
The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:
FDA AdComm to Review Investigational Alzheimer Agent Donanemab and Phase 3 Results
Amylyx Mulls Over Pulling AMX0035 Following Disappointing Phase 3 PHOENIX Findings
FDA Issues Complete Response Letter for Long-Acting Form of Glatiramer Acetate for Relapsing Multiple Sclerosis
Phase 2 PROCEED Trial of PACAP-Targeting Antibody Lu AG09222 in Migraine Announced
Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.
Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, Daniel Ontaneda, MD, an associate professor of neurology at the Cleveland Clinic Lerner College of Medicine, sat down to discuss the recently concluded Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum. Ontaneda, program committee vice-chair of the meeting, provided insight on a number of notable sessions and discussions that highlighted the recent advances in the MS field. In addition, he talked about the need to innovate clinical trials, ways to tackle progressive MS, and whether drug trials are truly assessing patients at the right time points. Furthermore, he discussed multi-stage trials, the potential role of Bruton tyrosine kinase (BTK) inhibitors, and how this year's meeting differs from previous ones.
Looking for more multiple sclerosis discussion? Check out the NeurologyLive® multiple sclerosis clinical focus page.
Episode Breakdown:
1:05 – Overviewing sessions from ACTRIMS Forum
13:10 – Innovating clinical trial design
16:15 – 2023 ACTRIMS vs 2024 ACTRIMS
20:20 – Neurology News Minute
23:30 – Testing combination approaches for progressive MS
26:45 – The impact of timing therapeutic interventions
This episode is brought to you by Medical World News, a streaming channel from MJH Life Sciences®. Check out new content and shows every day, only at medicalworldnews.com.
The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:
FDA AdComm to Review Investigational Alzheimer Agent Donanemab and Phase 3 Results
Amylyx Mulls Over Pulling AMX0035 Following Disappointing Phase 3 PHOENIX Findings
FDA Issues Complete Response Letter for Long-Acting Form of Glatiramer Acetate for Relapsing Multiple Sclerosis
Phase 2 PROCEED Trial of PACAP-Targeting Antibody Lu AG09222 in Migraine Announced
Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.
30 min